Olanzapine is associated with more rapid weight gain than haloperidol in people with first episode psychosis: Commentary

Evidence-Based Mental Health

Volumn 9, Issue 3, 2006, Pages 72-

  Lambert, Michael T ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Fort Worth Veterans Affairs Mental Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960405712     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebmh.9.3.72     Document Type: Note

References (5)

1. Lambert MT, Copeland LE, Sampson N, et al. New-onset type 2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30 March [Epub ahead of print].
2. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 2003;160:284-9. (Pubitemid 41110453)
3. American Diabetes Association. Consensus Development Conference on antipsychotic drugs, obesity, and diabetes. Diabetes Care 2004;27:596-601.
4. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64. (Pubitemid 34538833)
5. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine on risk of diabetes among patients with schizophrenia: population-based nested case-control study. BMJ 2002;325:243.